Enforcement Report - Week of November 29, 2023
Exela Pharma`s Generic Acetylcysteine Receives Approval in the U.S.
Rogue particles turning up in drugs has caused a plethora of recalls in recent years, most recently affecting pharma giants Pfizer and GSK. Now, North Carolina-based specialty drugmaker Exela Pharma Sciences has taken the contamination hit.
Exela Pharma Sciences, LLC Issues Voluntary Nationwide Recall of 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL, Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL, and ELCYS (cysteine hydrochloride Injection), USP 500 mg/10 mL Due to the Presence of Particulate Matter
Enforcement Report - Week of December 21, 2022
Exela Pharma Sciences, LLC Expands Voluntary Nationwide Recall of Sodium Bicarbonate Injection
Enforcement Report - Week of November 2, 2022
Exela's Generic Cupric Chloride Receives Approval in the U.S.
Lacerations aren’t typically the sort of side effect one associates with a faulty drug, but in Exela Pharma Sciences’ case, the threat has prompted a mass recall of an injectable used to treat a kidney disease complication.
Exela Pharma Sciences, LLC Issues Voluntary Nationwide Recall of Sodium Bicarbonate Injection